tbuckley/cabot-search huggingface dataset:
ABSENCE OF CORPORA LUTEA IN A CASE OF ATYPICAL UTERINE HEMORRHAGE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
Authors: J.-F. Chatal, J.-L. Harousseau, F. Griesinger, J. Meller, C. Renner, C. M. Kirsch, R. Naumann, J. Kropp, W. A. Wegener, D. M. Goldenberg
Journal: Journal of Clinical Oncology (2004)

2545 Background: A phase I/II, multi-center, dose-escalation trial was conducted to establish the safety, optimal dosing, and preliminary efficacy of 90Y-epratuzumab administered weekly for 2 or 3 consecutive wks to pts with B-cell NHL who failed ≥1 regimen of standard chemotherapy. Methods: Eligibility criteria included <25% BM involvement, plts >100,000 cells/mm3, and measurable disease by CT with no single mass >10 cm. Pts received 1.5 mg/kg/wk epratuzumab with 111In-epratuzumab co-administered the 1st wk. Twenty-six pts with a median of 3 prior treatments have been treated, including 15 pts without prior bone marrow transplant (BMT) at 5–10 mCi/m2/wk (total 90Y dose, 15–22.5 mCi/m2) and11 pts with prior BMT escalated separately at 2.5–5 mCi/m2/wk (total 90Y dose, 5–10 mCi/m2). Results: Dose escalation is continuing, with no serious AEs considered treatment-related. One pt in each escalation arm had protocol-defined DLT (>12 wk platelet recovery); otherwise, therapy was well tolerated with no significant toxicity besides transient hematologic depression, including 4 pts retreated without additional toxicity. 111In imaging demonstrated antibody tumor targeting, and hot/cold PK demonstrated stability of DOTA chelation ≥1 wk. In 22 pts with treatment evaluations, 13 pts (59%) had an objective response (OR) by IWG criteria, including pts with and without BMT [5/9 (56%) and 8/13 (62%), respectively], with indolent and aggressive disease [8/10 (80%) and 5/12 (42%), respectively], across histologies [follicular NHL, 9/12 (75%); DLCL, 2/4 (50%); mantle cell, 2/6 (33%)], and in pts failing rituximab (9/15, 60%). Most OR's were complete responses (CR/CRu, 9/13, 69%), and 3/5 pts assessed after CR onset now have responses >6 mo, including 2 pts continuing >1 yr. Conclusion: This study shows the feasibility and safety of a dose-fractionation schedule of a 90Y-labeled anti-CD22 Mab, obtaining therapeutic responses across all pt groups, including durable complete responses, and achieving higher cumulative doses than other RAIT agents given as single doses. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Immunomedics Immunomedics Immunomedics Immunomedics
ANTITYPHOID VACCINATION IN CHILDREN*
Authors: Frederick F Russell
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Marihuana Effects
Authors: James A. Halikas
Journal: JAMA (1971)

A study of 100 regular marihuana users indicated that marihuana use is usually a pleasant experience with few aversive effects, either during intoxication or afterwards. However, 16% reported that they "usually" experience one or more unpleasant acute or postintoxication effects, and a majority "occasionally" experience some aversive effect, including anxiety symptoms, feelings of derealization, and memory impairment.
Highlights
Journal: JAMA (2014)

Brief Intervention for Drug Use in Safety-Net Settings 492The effectiveness of brief interventions for problem drug use-particularly among disadvantaged patients-is unclear.In a randomized trial involving 868 patients receiving care at 7 safety-net primary care clinics, Roy-Byrne and colleagues found that compared with enhanced usual care, a 1-time brief intervention with attempted telephone booster did not significantly reduce self-reported past 30-day drug use.In an Editorial, Hingson and Compton discuss screening and intervention for drug use in primary care settings.
VIVISECTION.
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute polyarthritis associated with active Epstein-Barr virus infection
Authors: C. G. Ray
Journal: JAMA (1982)

Nine patients with an initial onset of symptoms of acute arthritis within the preceding four weeks were enrolled in a prospective serological study with clinical follow-up for six months to two years. Four adults with chronic rheumatoid arthritis and ten healthy adults were similarly studied. Serial titers measured included antibodies to Epstein-Barr virus (EBV) antigens, group B coxsackieviruses, rubella virus, cytomegalovirus, and herpes simplex virus. Serological evidence of active EBV infection was found in four of the patients with acute arthritis, none of the patients with chronic arthritis, and one of the ten healthy adults. There was no similar correlation between acute disease and presence of antibodies to the other viruses tested. We suggest that EBV may cause acute rheumatic illnesses more commonly than is currently appreciated but is probably not involved in the etiology of typical chronic rheumatoid arthritis. (<i>JAMA</i>1982;248:2990-2993)
Abstract 2563: A comparison of microsatellite instability analysis methods for detection of mismatch repair deficiency
Authors: Samantha R. Lewis, Shaun Peterson, Kathryn Oostdik, Heather Tomlinson
Journal: Cancer Research (2019)

Abstract Use of biomarkers for patient treatment stratification is an increasingly important topic with the recent FDA approval of Pembrolizumab and Nivolumab for microsatellite instability (MSI) high/mismatch repair (MMR) deficient cancers. This ground-breaking approval allows physicians to make patient treatment decisions based on molecular biomarker status. Thus, performance of detection methods for these biomarkers is of great importance. The gold standard for microsatellite instability (MSI) analysis is PCR followed by fragment analysis using capillary electrophoresis to resolve DNA fragment size. Recently, PCR followed by melt curve analysis and Next Generation Sequencing (NGS) have been presented as alternative approaches. In this set of experiments, these methods will be compared using a subset of human cancer samples. A cohort of matched cancer and adjacent normal FFPE samples were used for this comparison. From this cohort, individuals were selected that contained subtle MSI shifts, low tumor volume, or heterozygosity at microsatellite loci. Samples from these individuals were tested for MSI by either fragment or melt curve analysis or by sequencing. Samples were then classified as MSI-High, MSI-Low or microsatellite stable (MSS) according to manufacturer specifications for melt curve analysis or by an interpretive software for fragment analysis and NGS. Preliminary results indicate that there may be differences in sensitivity when using challenging samples with melt curve analysis compared to the gold standard method, fragment analysis. The standard method for determining MSI status utilizes PCR and fragment analysis. Recently, melt curve analysis and NGS have been proposed as alternative methods. We present preliminary findings of decreased sensitivity with melt curve compared to fragment analysis. Additional studies with a larger, more diverse sample set will be required to define this relationship further. Citation Format: Samantha R. Lewis, Shaun Peterson, Kathryn Oostdik, Heather Tomlinson. A comparison of microsatellite instability analysis methods for detection of mismatch repair deficiency [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2563.
Regional Consultants
Authors: C. F. Allenby, J. H. Bayliss, B. Bazeley, A. A. Buchanan, H. Bentley, B. Cashman, R. Chignell, P. Dutton, A. W. Ferguson, S. K. Ganczakowski, J. I. H. Hadfield, R. G. Hallam, J. R. Hassard, M. D. Hosford, D. W. Lacey, D. Lewes, R. G. Miller, G. R. C. Peatfield, J. R. Saunders, J. C. Valentine, J. C. Watts, R. H. Welch
Journal: BMJ (1970)
The Chemistry of the Terpenes.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Availability of Frozen Serum Panels
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Availability of Frozen Serum Panels Get access JNCI: Journal of the National Cancer Institute, Volume 72, Issue 6, June 1984, Pages 1465–1466, https://doi.org/10.1093/jnci/72.6.1465-g Published: 01 June 1984
Genetic Influence on the Systems Biology of Sickle Stroke Risk Detected by Endothelial Gene Expression.
Authors: Robert P. Hebbel, Peng Wei, Aixiang Jiang, Cheryl Hillery, J. Paul Scott, Stephen C. Nelson, Judy Enenstein, Liming Milbauer, Vidya Bodempudi, Wei Pan, Betsy Hirsch, James N. Topper, Ruey-Bing Yang
Journal: Blood (2007)
Correction: Paternal radiation exposure and leukaemia in offspring: the Ontario case-control study
Journal: BMJ (1993)

Children's health as measured by height and birth weight is better in rural areas than in urban areas * Children's height and birth weight are poorer in deprived areas in all rural and urban settings * Despite this the difference between rural and urban areas in height and birth weight remains after differences in deprivation have been accounted for * The reasons for the rural health advantage are not clear but they are not an artefact * The results support claims that children in urban areas have greater health needs than those in rural areas suggested that latitude acted as a proxy measure of social factors which varied in a north-south gradient and were not otherwise measured.We doubt this and suggest that the rural-urban difference was genuine.
Serum creatinine
Authors: G. Dunea
Journal: JAMA (1968)

Determination of the serum creatinine concentration is widely used in the clinical evaluation of the patient with suspected renal disease. It provides an approximate estimation of the glomerular filtration rate and is a useful test, provided its limitations are appreciated. The method for determination of creatinine in the laboratory is based on the reaction described by Jaffe in 1886, namely, the development of a yellow or red color by the interreaction of creatinine and picric acid in an alkaline solution.<sup>1</sup>The presence in the serum of certain substances, usually called "chromogens," which give a similar color with picric acid, presents a problem in the determination and interpretation of the serum creatinine. Some of the chromogen substances are unknown. Others may include acetone, pyruvic and ascorbic acid, proteins, barbiturates, phenolsulfonphthalein, and sodium sulfobromophthalein. Their concentration varies with the method of deproteinization of the serum and the time allowed for development
Anlotinib in patients with recurrent platinum-resistant or refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study.
Authors: Boer Shan, Wenbin Shen, Huaying Wang
Journal: Journal of Clinical Oncology (2020)

6061 Background: Recurrent platinum-resistant or refractory ovarian carcinoma is difficult to treat, and how to improve the treatment effect of these patients is still an urgent problem to solve. Anlotinib is a new multi-target tyrosine kinase inhibitor and its anti-tumor vascular targets include VEGFR, PDGFR and FGFR. Previous researches have shown clinical antitumor activity of anlotinib in various cancers, including the phase I study on gynecologic tumor. This phase II study (ChiCTR2000029654) aims to further evaluate the safety and efficacy of anlotinib in patients with recurrent or refractory ovarian carcinoma. Methods: Patients who have previously received second-line or more chemotherapy, with histopathologically confirmed ovarian high-grade serous gonadal carcinoma (including salpingocarcinoma and peritoneal carcinoma), ECOG 0-2 were considered eligible for enrollment. Anlotinib was administered orally (12 mg qd, d1-14; 21 days per cycle) till disease progression, death or intolerant toxicity. Therapeutic effects are evaluated every 6 weeks. The primary endpoint was objective response rate (ORR) and the secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety and quality of life (QOL). Results: Between 2019 March to 2020 January, 15 patients (female) with FIGO histopathological stage IA(6.7%), IIIA (73.3%), IIIC (6.7%) and IV (13.3%) were enrolled and 14 patients were evaluable with a median age of 59 years (range: 47-69). The mean follow-up period is 3.5 months (95% CI: 2.1-4.8). Therapeutic evaluation showed the incidence of partial response, stable disease and progression disease was 14.3%, 57.1% and 28.6% respectively, yielding the ORR of 14.3% (2/14; 95% CI: 1.8%-42.8%) and the DCR of 71.4% (10/14; 95% CI: 41.9%-91.6%). The median PFS was not reached. Most of the occurring AEs were grade 1, including hypertention (57.1%), fatigue (50.0%), hand-foot syndrome (35.7%), hoarseness (14.3%), diarrhea (7.1%), gum-pain (7.1%), decrease in leukocyte count (6.7%) and urine protein (7.1%). Only cancer pain (7.1%) was grade 2. No high grade AE was observed in these 14 patients. Neither unexpected safety signals nor treatment related death occurred. Conclusions: Anlotinib showed a promising efficacy with a favourable toxicity profile for patients with recurrent platinum-resistant or refractory ovarian carcinoma. And we will report more results ahout anlotinib in the future. Clinical trial information: ChiCTR2000029654.
Autologous Transfusion
Authors: Herbert Silver
Journal: JAMA (1976)

ONE DAY a middle-aged married couple came to the blood bank requesting that a unit of blood be drawn from the husband. The wife was scheduled for surgery in ten days and the blood to be drawn was to be kept for possible use at that time. Although the woman had been told that there was only a remote possibility that a transfusion would be required she thought that if she were to get any blood she wanted it to be "safe" blood from someone she thought had not had hepatitis or any other disease with which she could be infected through transfusion. Her fears were prompted by recent federal interest in hepatitis transmission through blood, as well as by malpractice cases concerned with instances of hepatitis resulting from blood transfusion (all of which have been covered in depth by newspapers and other lay publications). It was soon learned that
Disruption of BIRC3 associates with Fludarabine Chemorefractoriness in TP53 Wild Type Chronic Lymphocytic Leukemia
Authors: Marco Fangazio, Silvia Rasi, Tiziana Vaisitti, Sara Monti, Stefania Cresta, Alessio Bruscaggin, Valeria Spina, Francesco Forconi, Sabina Chiaretti, Anna Guarini, Silvia Deaglio, Robin Foà, Gianluca Gaidano, Davide Rossi
Journal: Blood (2011)
HIV Seroconversion Among High-Risk Women in New York City
Authors: Pauline Thomas
Journal: JAMA (1994)

<h3>To the Editor.</h3> —Incidence of human immunodeficiency virus (HIV) infections in men and women may predict the magnitude of the acquired immunodeficiency syndrome (AIDS) epidemic, to evaluate the efficacy of prevention programs and to design vaccine trials. Surveys of HIV-1 seroincidence in small samples of high-risk women in the United States outside New York City (NYC) have reported annual rates of 3% to 5%.<sup>1,2</sup>Six-month seroincidence among 377 women attending a NYC public clinic for sexually transmitted diseases was 1.7%.<sup>3</sup> We have estimated the HIV seroconversion rate among high-risk, HIV-negative women in NYC as part of the NYC Perinatal HIV Transmission Collaborative Study. Pregnant women at risk for HIV infection (having a history of injection drug use [IDU], crack cocaine use, or sexual exposure to a man with history of IDU) were enrolled at six NYC hospitals between 1986 and 1992 as controls in a prospective study of
Delirium Tremens
Authors: Marvin A. Block
Journal: JAMA (1965)

<h3>To the Editor:—</h3> I cannot say that I disagree completely with Dr. Halvorsen's statement regarding the prevention of delirium tremens by gradual withdrawal of alcohol, or the so-called tapering off treatment. There are many who still adhere to this method. The substitution of other drugs, however, will often facilitate the withdrawal from acute alcohol intoxication, diminish the time of the withdrawal period, and bring about a more rapid recovery from the acute phase. This often is a matter of clinical judgment of the therapist. In many years of treating alcoholics, I have seen delirium tremens occur in the acutely intoxicated stage as well as a withdrawal phenomenon. I have also seen it occur where the daily amount of alcohol intake is diminished and not stopped. Strangely enough, many severe alcoholics never go into delirium tremens, even with withdrawal. Perhaps one of the most important reasons for not prescribing alcohol in
Psychoactive substance dependence among trauma center patients
Authors: C. A. Soderstrom
Journal: JAMA (1992)

<h3>Introduction.</h3> —The practice of assessing only trauma patients with elevated blood alcohol concentrations (BACs) or positive drug screens for psychoactive substance use disorders (PSUDs) was evaluated. <h3>Methods.</h3> —Twenty-four BAC-negative (BAC<sup>-</sup>) (BAC, 0) and 21 BAC-positive (BAC<sup>+</sup>) (BAC, ≥22 mmol/L or 100 mg/dL; mean, 41 mmol/L; range, 24.3 to 79 mmol/L) adult trauma patients were evaluated for alcoholism and other PSUDs using the Structured Clinical Interview (SCI) from the<i>Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (DSM-III-R)</i>. Approximately half were vehicular crash victims and 78% were men. <h3>Results.</h3> —A total of 64 PSUDs were diagnosed in 31 (68.9%) of the 45 patients; all but one was for dependence (vs abuse). Of the BAC<sup>+</sup>patients, 14 (66.7%) met<i>DSM-III-R</i>criteria for alcohol dependence, 11 (78.6%) of whom also had other PSUDs not related to alcohol. Two other BAC<sup>+</sup>patients had nonalcohol PSUDs. Of the BAC<sup>-</sup>patients, 11 (45.8%) had alcohol dependence, six (54.5%) of whom also had nonalcohol PSUDs. Another four BAC<sup>-</sup>patients had nonalcohol PSUDs. Overall, 76.2% of the BAC<sup>+</sup>patients and 62.5% of the BAC patients had a diagnosis of psychoactive substance dependence. <h3>Conclusion.</h3> —All patients admitted to trauma centers should be assessed for alcoholism and other PSUDs. (<i>JAMA</i>. 1992;267:2756-2759)